Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

33.96 +0.26 (+0.77%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gsk Plc ADR

< Previous 1 2
...
29 30 31 32 33 34 35 36 Next >
Here's Why 2022 Could Be a Huge Year for GlaxoSmithKline
Another big step in preventing HIV and AIDS has been taken and GlaxoSmithKline is at the forefront. 
Via The Motley Fool
Exposures Product Safety
Perfumes Of Arabia
Downtrends do eventually run out of pessimistic steam, but it can take a while. 
Via Talk Markets
New Covid-19 Vaccines Continue to Be Developed by Biotech Firms Seeking to Improve the Jab
FN Media Group Presents USA News Group News Commentary Vancouver, BC –October 6, 2021 – USA News Group – As vaccine passport programs continue to roll out in new markets across the globe, especially in... 
Via FinancialNewsMedia
Exposures COVID-19
Best Pharmaceutical Stocks To Buy In 2021
The global pharmaceutical market has experienced significant growth in recent years. As of end-2020, the total global pharmaceutical market was valued at about 1.27 trillion U.S. dollars. 
Via Talk Markets
Sweet Smell Of Recovery
Markets today saw many reversals of moves by ADR companies in the course of the day, mainly because of macro changes. 
Via Talk Markets
Global Antibiotics Drugs Market: Which Application Willgain the Lion'S Share? with Top Companies Like:Johnson & Johnson, Sanofi-Aventis, Enanta Pharmaceuticals
QY Research has used its tons of research and analysis experience and deeper knowledge to comprehensively study the global Antibiotics Drugs market. This report promises sound market understanding for... 
Via SBWire
Tesla and Merck Give Investors Some Hope
Friday’s rally appears to have lost its momentum over the weekend because stock futures are trading lower before Monday’s open. China’s troubled real estate... 
Via Benzinga
September Ends
Congress managed to pass a bipartisan short-term spending bill avoiding a crisis over the debt ceiling. 
Via Talk Markets
GlaxoSmithKline, Merck KGaA End $4B Cancer Drug Pact
Merck KGaA (OTC: MKGAF) and GlaxoSmithKline Plc (NASDAQ: GSK) have ended their $4 billion collaboration on cancer treatment, bintrafusp alfa. Merck said... 
Via Benzinga
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (... 
Via Benzinga
Exposures COVID-19
A Bit Of A Recovery
While Germany remains without a government, Japan has a new prime minister who will lead his party in the election this week. 
Via Talk Markets
ViiV Healthcare's Dovato Combo Regime Shows Encouraging Long Term Data In HIV Patients
ViiV Healthcare, a joint venture between GlaxoSmithKline plc (NYSE: GSK), Pfizer Inc (NYSE: PFE), and Shionogi, presented three-year results ... 
Via Benzinga
ViiV In-Licenses Third-Gen HIV Targeting Compound From Shionogi
ViiV Healthcare, majority-owned by GlaxoSmithKline plc (NYSE: GSK), Pfizer Inc (NYSE: PFE), and Shionogi, has announced an exclusive collaboration... 
Via Benzinga
GSK, Pfizer Backed Long-Acting HIV Med Under FDA Priority Review As Preventative Option
The FDA has accepted and granted Priority Review to ViiV Healthcare's marketing application seeking approval for injectable cabotegravir long-acting for... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27) Acceleron Pharma Inc. (... 
Via Benzinga
Sanofi Stops Work On Its mRNA COVID-19 Vaccine: What You Need To Know
Sanofi SA (NASDAQ: SNY) is dropping plans for its mRNA-based COVID-19 vaccine because it believes it will be too late in reaching the market, STAT news reported. Sanofi... 
Via Benzinga
Exposures COVID-19
4 No-Brainer Pharmaceutical Stocks to Buy in October
While the resurgence of COVID-19 cases is driving the demand for vaccines, booster shots, and other related solutions, an aging population is expected to be a key growth driver for the pharmaceutical... 
Via Talk Markets
Exposures COVID-19
Glaxo - Vir Biotech's COVID Treatment Approved In Japan
Japan's health ministry expert committee has approved GlaxoSmithKline Plc (NYSE: GSK) - Vir Biotechnology Inc's (NASDAQ: VIR) sotrovimab, a COVID-19... 
Via Benzinga
Analyst Upgrades Sanofi On COVID-19 Vaccine Optimism
Sanofi SA (NASDAQ:SNY) shares traded higher by 0.4% on Mond... 
Via Benzinga
Exposures COVID-19
Acceleron Stock Heats Up On $11 Billion Takeover Rumor; So, Who's The Buyer?
A biotech working in lung and blood diseases, as well as cancer, could be acquired. 
Via Investor's Business Daily
China's Rescue Of Evergrand
The number of jobless last week was higher than the forecast, at 351,000 vs 320,000. The recovery is lagging. 
Via Talk Markets
Green Hygienics Holdings To Raise $100M Via Green Bond Offering
Hemp company Green Hygienics Holdings Inc. (OTCQB:GRYN) is ... 
Via Benzinga
Why Are Theravance Bio Shares Plummeting Premarket Today?
Theravance Biopharma Inc (NASDAQ: TBPH) will reduce its headcount by approximately 75% (estimated 270 positions), with most of the lay off to complete in November... 
Via Benzinga
4 Top Healthcare Stocks to Buy in September
In addition to playing a major role in helping the world fight the COVID-19 pandemic, the healthcare industry is making solid progress in addressing the rising health issues faced by an aging global... 
Via Talk Markets
Exposures COVID-19
CureVac Shares Fall After Cutting COVID-19 Vaccine Production Plans
CureVac BV has canceled contract manufacturing deals for its experimental COVID-19 vaccine with two prospective partners. 
Via Talk Markets
Exposures COVID-19
CureVac Shares Fall After Cutting COVID-19 Vaccine Production Plans
CureVac BV (NASDAQ: CVAC) has canceled contract manufacturing deals for its experimental COVID-19 vaccine with two prospective partners. The Company would... 
Via Benzinga
Exposures COVID-19
Why Experts Believe Antibody Treatments Hold The Potential To Reduce Need For Hospitalization For COVID-19 Patients
Via FinancialNewsMedia
Exposures COVID-19
Pete Najarian Sees Unusual Options Activity In Capri Holdings And GlaxoSmithKline
On CNBC's "Fast Money Halftime Report," Pete Najarian said he saw a buyer of 5,000 contracts of the November $57.50 calls in Capri Holdings Ltd (NYSE: CPRI) in the... 
Via Benzinga
Delta Variant Fears Continue
The jobless level fell to 310,000 whereas the consensus forecast was for 335,000, so risks of inflation are higher. 
Via Talk Markets
This Med Tech Innovator Just Doubled, And It Can Do It Again
We’re here to crush the market with the foremost innovative tech leaders. 
Via Talk Markets
< Previous 1 2
...
29 30 31 32 33 34 35 36 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.